Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several
conjugates successfully translated into clinical practice. The conjugation of therapeutic …

Targeted delivery combined with controlled drug release has a pivotal role in the future of
personalized medicine. This review covers the principles, advantages, and drawbacks of …

Realization of the immense potential of nanomaterials for biomedical applications will
require a thorough understanding of how they interact with cells, tissues, and organs. There …

Although immune checkpoint blockade has shown initial success for various cancers, only a
small subset of patients benefits from this therapy. Some chemotherapeutic drugs have been …

Nanomedicine is defined as “the application of nanotechnology to medicine, including the
use of nanometer-sized carrier materials for facilitating disease diagnosis, disease treatment …

The majority of the human genome encodes RNAs that do not code for proteins. These non-
coding RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and …

Polymer–drug conjugates are becoming established as a shining platform for drug delivery.
Incorporation of pH-responsive linker between drug and polymer is expected to realize …

Enhanced permeability and retention (EPR) and the (over-) expression of angiogenesis-
related surface receptors are key features of tumor blood vessels. As a consequence, EPR …

This overview focuses on bioconjugates of water-soluble polymers with low molecular
weight drugs and proteins. After a short discussion of the origins of the field, the state-of-the …

Treatment of cancer patients with taxane-based chemotherapeutics, such as paclitaxel
(PTX), is complicated by their narrow therapeutic index. Polymeric micelles are attractive …